Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

By Global News Feed

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

Link:
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

By Global News Feed

– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine –

Original post:
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights

By Global News Feed

- Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 - - Expanded into New Zealand market and increased market share in existing regions -

Read more:
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

By Global News Feed

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

Follow this link:
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

By Global News Feed

WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DISC-3405 for the treatment of patients with polycythemia vera (PV).

Link:
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market

By Global News Feed

NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced the acquisition of all the issued and outstanding common shares of Aimia Pet Healthco Inc. (‘Aimia’). Better Choice will now be in a position to manage the clinical trials internally in hopes to develop a supplement to support weight loss in domestic animals.

Read this article:
Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market

A New Gig in the Science World – The New York Times

By Stell Cell Research

Good morning. Its Wednesday. Well meet the new president and chief executive of a foundation that backs stem cell research. Well also get details on a $5 million fine in a New Jersey tax break scandal.

Jennifer Raab heard about the space launch while being interviewed for a job at the New York Stem Cell Foundation that unexpectedly turned emotional.

Valentina Fossati, a scientist with the foundation, mentioned that test tubes would be part of the payload on a private mission to the International Space Station. The test tubes would contain three-dimensional models of brain tissue that scientists at the foundation had made from stem cells. Fossati said the scientists hoped to learn whether space was the place to study neurodegenerative diseases like Parkinsons disease and multiple sclerosis.

Then Fossati said that she had M.S. herself.

That was very moving, Raab said, to realize that someone had turned her own challenges into working on solving a problem for the general population.

Raab was hired as president and chief executive of the foundation. The space mission was launched on her third day on the job. The project, conducted in collaboration with other research institutions, will study the cells when they are brought back to earth. The researchers will look for changes brought on by microgravity in space and whether such changes could be applied to work on diseases like Parkinsons or M.S.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

See more here:
A New Gig in the Science World - The New York Times

Researchers discover new class of compound that targets cancer stem cells – News-Medical.Net

By Stell Cell Research

Many cancer therapies, in addition to producing numerous side effects, fail to achieve complete tumour remission, partly due to the presence of cancer stem cells, which are difficult to eradicate. These cells can self-renew and play a key role in tumor recurrence and metastasis processes, so there is significant interest in developing therapies that target this subset of tumour cells.

A collaboration between chemists from the Center for Research in Biological Chemistry and Molecular Materials (CiQUS), led by Prof. JL Mascareas, and cell biologists from the CSIC (Instituto de Investigaciones Biomdicas Sols-Morreale, IIBM CSIC-UAM, Madrid), led by Dr. Bruno Sainz, has led to the discovery of a new class of compound that targets cancer stem cells and reduces their potential to generate tumors. For some years, Prof. Mascareas' laboratory has been conducting basic research on certain molecules based on metal complexes that can interact very selectively with DNA. These findings have allowed Dr. Sainz's group to conduct extensive studies with mice implanted with patients' tumors, demonstrating a powerful antitumor effect of these complexes. The scientists have demonstrated anticancer effects in pancreatic, colorectal, and osteosarcoma tumors, with low secondary toxicity, and studies on other types of cancer are currently underway.

Cancer stem cells rely on mitochondrial respiration to survive and evade the immune system's defenses, which represents a metabolic Achilles' heel. Mechanistic studies carried out this time suggest that the new compound, called Ru1, promotes a decrease in the expression of genes necessary for this respiration, the main energy source for these cells, causing them to lose their cancerous potential. Dr. Sainz's group has also demonstrated that combined therapies with other antitumor agents are possible, resulting in additive effects.

The preliminary results of the scientific work, which also includes contributions from the USC's ACUIGEN group, have just been published in a leading cancer research journal. All these studies have been made possible thanks to the support of different entities, including the Ignicia program (Xunta de Galicia), the Spanish Association Against Cancer, or the CaixaImpulse program ("la Caixa" Foundation), and the project is currently in an advanced stage for its transfer and preclinical valorization.

Source:

Journal reference:

Alcal, S., et al. (2024). Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy.Journal of Experimental & Clinical Cancer Research. doi.org/10.1186/s13046-023-02931-7.

More:
Researchers discover new class of compound that targets cancer stem cells - News-Medical.Net

Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. – InvestorsObserver

By Stell Cell Research

Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. "Revolutionizing Regenerative Medicine: The Booming Frontier of Synthetic Stem Cells Unleashes Hope and Healing" PMI Leads the Way

Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- According to the recent research study, the Synthetic Stem Cells Market size was valued at about USD 8.9 Billion in 2024 and expected to grow at CAGR of 23.3% to extend a value of USD 60.1 Billion by 2034.

What is Synthetic Stem Cells?

Synthetic stem cells can be designed in laboratories by mimicking the properties of natural stem cells, such as their self-renewal capacity and pluripotency (ability to differentiate into multiple cell types). These artificial cells are often created using bioengineering techniques and may involve the use of biomaterials, genetic manipulation, or other advanced technologies. The field of synthetic stem cells holds promise for various medical applications, including regenerative medicine, tissue engineering, and disease treatment. By harnessing the potential of synthetic stem cells, researchers aim to develop innovative therapies for conditions such as injuries, degenerative diseases, and other disorders that involve damaged or malfunctioning tissues.

Driving Factors:

Restrain Factors:

Get Access to Free Sample Research Report with Latest Industry Insights:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3911

*Note: PMI Sample Report includes,

Report scope:

By Region - North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Top Leading Players in Synthetic Stem Cells Market:

Download PDF Brochure:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/3911

Emerging Trends and Opportunities in Synthetic Stem Cells Market:

Challenges of Synthetic Stem Cells Market:

Detailed Segmentation:

Key highlights of the Synthetic Stem Cells Market:

Any query or customization before buying:

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/3911

Explore More Insights:

Blog: http://www.prophecyjournals.com

Follow us on:

LinkedIn | Twitter | Facebook | YouTube

See the article here:
Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. - InvestorsObserver